Search
Vir Biotechnology Inc
VIRAdd to Watchlist
9.865USD
+0.305+3.19%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.59BMarket Cap
LossP/E TTM
More Details of Vir Biotechnology Inc Company
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes infectious disease programs for chronic hepatitis delta and chronic hepatitis B infections and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. It also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Tobevibart is an investigational neutralizing monoclonal antibody (mAb) that has been engineered for immune engagement and targets a conserved region on the hepatitis B surface antigen (HBsAg). Elebsiran is an investigational HBV-targeted small interfering RNA (siRNA) that reduces HBsAg. Its pipeline includes VIR-5818, VIR-5500, VIR-5525, and HIV Cure. It also has rights to the PRO-XTEN masking platform for oncology and infectious disease.
Vir Biotechnology Inc Info
Ticker SymbolVIR
Company nameVir Biotechnology Inc
IPO dateOct 11, 2019
CEODe Backer (Marianne)
Number of employees408
Security typeOrdinary Share
Fiscal year-endOct 11
Address1800 Owens Street
CitySAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94158
Phone14159064324
Websitehttps://www.vir.bio/
Ticker SymbolVIR
IPO dateOct 11, 2019
CEODe Backer (Marianne)
Company Executives of Vir Biotechnology Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
233.10K
-15.93%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
40.66K
+19.68%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
31.81K
+25.15%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
18.67K
+42.86%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
8.22K
-321.82%
Dr. Vicki L. Sato, Ph.D.
Dr. Vicki L. Sato, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. C. Elliott Sigal, M.D., Ph.D.
Dr. C. Elliott Sigal, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Janet Napolitano, J.D.
Ms. Janet Napolitano, J.D.
Independent Director
Independent Director
--
--
Dr. Mark Eisner, M.D.
Dr. Mark Eisner, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Marianne De Backer, Ph.D.
Dr. Marianne De Backer, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
233.10K
-15.93%
Mr. Robert J. (Bob) More
Mr. Robert J. (Bob) More
Independent Director
Independent Director
40.66K
+19.68%
Mr. Jeffrey S. (Jeff) Hatfield
Mr. Jeffrey S. (Jeff) Hatfield
Independent Director
Independent Director
31.81K
+25.15%
Dr. Norbert W. Bischofberger, Ph.D.
Dr. Norbert W. Bischofberger, Ph.D.
Independent Director
Independent Director
18.67K
+42.86%
Ms. Saira Ramasastry
Ms. Saira Ramasastry
Independent Director
Independent Director
14.62K
--
Ms. Vanina De Verneuil, J.D.
Ms. Vanina De Verneuil, J.D.
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
8.22K
-321.82%
FAQs
Who are the top five shareholders of Vir Biotechnology Inc?
The top five shareholders of Vir Biotechnology Inc are: Dr. Marianne De Backer, Ph.D.
How many institutions hold shares of Vir Biotechnology Inc (VIR)?
As of 2026Q1, 497 institutions hold shares of Vir Biotechnology Inc, with a combined market value of approximately 130.35M, accounting for 77.29% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 9591956.00.